SMARTT Projects | Treatments for Lung, Heart, Blood Diseases | SRI International

Toggle Menu
gloved hand catching pill capsules coming out of a dispenser

SMARTT Projects: Treatments for Lung, Heart, Blood Diseases

Through a broad range of services for the National Institutes of Health, SRI is accelerating preclinical development of potential therapies for diseases that affect millions of people.

According to the National Heart, Lung, and Blood Institute (NHLBI), cardiovascular, lung, and blood diseases accounted for 43 percent of all deaths in the U.S. in 2006. The economic cost of these diseases is expected to reach $705 billion in 2011—23 percent of the total economic cost of all illnesses, injuries, and deaths.

SRI researchers support NHLBI’s Science Moving towArds Research Translation and Therapy (SMARTT) program, which provides preclinical, manufacturing, and regulatory guidance and resources that help novel therapeutics move through the drug development process toward the clinic. SMARTT also provides NHLBI investigators with a tailored approach that identifies the fastest route to an Investigational New Drug (IND) application.

For the NHLBI, SRI leads the Pharmacology and Toxicology Center and the Small Molecule Production Facility, which provides National Institutes of Health (NIH) investigators and various organizations with rapid and cost-effective studies of potential therapies. The goal is to accelerate the translation of research from bench to bedside. Researchers conduct pharmacology and preclinical studies of candidate drugs, in addition to developing treatment regimens and conducting efficacy studies. At the production facility, researchers formulate, analyze, and manufacture active pharmaceutical ingredients into dosage forms used in clinical trials.

SRI has more than 40 years of successful experience with preclinical development programs for NIH. To date, SRI has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market.

This project has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contracts No. HHSN268201100015C and HHSN268201100017C.